<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872090</url>
  </required_header>
  <id_info>
    <org_study_id>P/2015/255</org_study_id>
    <nct_id>NCT02872090</nct_id>
  </id_info>
  <brief_title>Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>LAB-Card</acronym>
  <official_title>Effects of Long Acting Bronchodilators on CARDiac Autonomic Nervous System Control in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this interventional, randomized, double-blind, monocentric, cross-over study is to
      quantify the possible deleterious effect on the cardiac autonomic nervous system control of
      two long-acting anticholinergic bronchodilatators (tiotropium and glycopyrronium) and one
      beta-2 agonist long-acting bronchodilatator (indacaterol ) in patients with mild COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-over study with randomization in terms of 4 treatments: two long-acting
      muscarinic antagonists (tiotropium and glycopyrronium), one long-acting beta-adrenoceptor
      agonist(indacaterol) and placebo.

      Each subject will pass 4 experimental random sessions, separated by at least 48 hours given
      the pharmacokinetic properties of the drugs tested. During each of the 4 sessions, blood
      pressure will be measured. Drugs inhaled by the patient will be prepared and administered by
      the nurse according to the randomization schedule. Patients and investigators will be blinded
      regarding the administered drug/placebo (anonymized inhaler). After 15 minutes (at rest, at
      neutral temperature), patients will have continuous measurement of blood pressure and heart
      rate (by a sphygmomanometer) (1) in supine position and (2) after a passive tilt test on a
      tilt test table.

      A flow-volume loop (BDV) will be performed after the tilt table test (measurement of Forced
      expiratory volume in 1 second (FEV1) and FVC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low-frequency (LF)/High-frequency (HF) ratio in supine position during a tilt table test after bronchodilators inhalation</measure>
    <time_frame>10 minutes</time_frame>
    <description>For each patient, the LF/HF ratio after inhalation of an active drug (indacaterol or glycopyrronium or tiotropium) will be compared to LF / HF ratio measured after inhalation of a placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Slope of baroreflex in supine position</measure>
    <time_frame>10 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LF / HF ratio derived from the spectral analysis of R-R intervals measured after verticalisation during a tilt table test</measure>
    <time_frame>10 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total spectral power during a tilt table tes</measure>
    <time_frame>20 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of HF (gross value then normalized according to the average R-R interval) during a tilt table tes</measure>
    <time_frame>20 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RMSSD (Root Mean Square of the Successive Differences) index during a tilt table test</measure>
    <time_frame>20 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability in blood pressure during a tilt table test</measure>
    <time_frame>20 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive once a week during 4 weeks, in the order: indacaterol, tiotropium, glycopyrronium and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive once a week during 4 weeks, in the order: tiotropium, glycopyrronium, placebo and indacaterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive once a week during 4 weeks, in the order: glycopyrronium, placebo, indacaterol and tiotropium,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive once a week during 4 weeks, in the order: placebo, indacaterol and tiotropium and glycopyrronium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <description>inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium</intervention_name>
    <description>inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>photoplethysmography</intervention_name>
    <description>inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with FEV1 / FVC &lt;70%

        Exclusion Criteria:

          -  beta blocker

          -  supraventricular rhythm disorder

          -  previous history of respiratory disease other than COPD

          -  diabetes

          -  autonomic dysfunction

          -  dysautonomia

          -  renal failure

          -  long-term oxygen therapy

          -  history of psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu VEIL-PICARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthieu VEIL-PICARD</last_name>
    <email>matthieuveil@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise ROBERT</last_name>
      <email>e1robert@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>bronchodilatators</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>cardiovascular system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

